Início › Colite ulcerativa › Ohio
Ensaios clínicos de Colite ulcerativa em Ohio
26 estudos para Colite ulcerativa estão buscando participantes em locais em Ohio.
Cidades em Ohio
Texto oficial do estudo (Inglês)
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastro Health Research - Cincinnati, Cincinnati
- DSI Research Northridge LLC, Dayton
- Gastro Health Research - Liberty Township, Liberty Township
- e mais 3
RecrutandoFase 4
Idades de 18 a 80 · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT06581328A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
- University Hospitals Cleveland Medical Center /ID# 271831, Cleveland
RecrutandoFase 3
Idades de 2 a 17 · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07071519A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- GCGA Physicians, LLC dba / Gastro Health Research, Cincinnati
- NexGen Research, Lima
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT06598943A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-025, Brunswick
- Site US-023, Dayton
- Site US-027, Westlake
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07845487Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
- Xencor Investigative Site, Beavercreek
RecrutandoFase 1/2Voluntários saudáveis bem-vindos
Idades de 18 a 75 · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT06619990Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Dayton Gastroenterology - Englewood /ID# 284065, Englewood
- Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07697456A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecrutandoFase 3
Idades 3 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06663332A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- Cleveland Clinic, Cleveland
RecrutandoFase 2/3
Idades de 2 a 17 · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT05076175Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
RecrutandoFase 3
Idades de 18 a 70 · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06937086Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT03816345LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Dayton Gastroenterology, LLC, Dayton
RecrutandoFase 2
Idades de 18 a 80 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07186101LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- Ohio State University, Hilliard
- DSI Research, LLC d/b/a ObjectiveHealth Clinical Research - Springboro, Springboro
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
RecrutandoFase 2
Idades de 18 a 80 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07415044Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
- Cleveland Clinic Foundation, Cleveland
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07513181A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- University of Cincinnati, Cincinnati
- Ohio Gastroenterology group, Inc., Columbus
- Gastro Intestinal Research Institute of Northern Ohio, LLC., Westlake
RecrutandoFase 4
Idades de 18 a 65 · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT06095128A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Ohio Gastroenterology Group Inc. - Site Number: 8400006, Columbus
- OSU Wexner Medical Center - Site Number: 8400077, Columbus
- North Shore Gastroenterology Research - Site Number: 8400130, Westlake
RecrutandoFase 3
Idades de 16 a 80 · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT07185009A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- Great Lakes Gastroenterology Research, LLC, Mentor
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT07577856An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Gastroenterology & Hepatology Specialists, Inc. - Site Number: 8400139, Canton
- Ohio Gastroenterology Group Inc. - Site Number: 8400006, Columbus
- OSU Wexner Medical Center - Site Number: 8400077, Columbus
- e mais 4
RecrutandoFase 3
Idades de 16 a 80 · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT07184996Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of Cincinnati, Cincinnati
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT07237516An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
- University of Cincinnati College of Medicine, Cincinnati
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
RecrutandoEstudo observacional
Idades de 18 a 64 · Todos os sexos · Atualizado em 9 de jul. de 2026 · NCT06398626A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
- University Hospitals Cleveland Medical Center Rainbow Babies & Children's Hospital, Cleveland
- University Hospitals Cleveland Medical Center, Cleveland
RecrutandoFase 2
Idades de 12 a 17 · Todos os sexos · Atualizado em 8 de jul. de 2026 · NCT05287126A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Children's Clinic, Cleveland
- Cleveland Clinic, Cleveland
RecrutandoFase 3
Idades de 2 a 17 · Todos os sexos · Atualizado em 22 de jun. de 2026 · NCT06405087A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
RecrutandoFase 3
Idades 2 e acima · Todos os sexos · Atualizado em 7 de mai. de 2026 · NCT05442567ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool
- Gastro Intestinal Research Institute of Northern Ohio,, Westlake
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades 22 e acima · Todos os sexos · Atualizado em 28 de abr. de 2026 · NCT06810518A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cincinnati
- Mirador Therapeutics Selected Site, Liberty Township
RecrutandoFase 2
Idades de 18 a 80 · Todos os sexos · Atualizado em 12 de mar. de 2026 · NCT07113522Evaluation of the SMART IBD App in Pediatric IBD
- Cincinnati Children's Hospital Medical Center, Cincinnati
Recrutando
Idades de 13 a 17 · Todos os sexos · Atualizado em 21 de nov. de 2025 · NCT07195123Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- University of Cincinnati, Cincinnati
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 8 de mai. de 2025 · NCT06750731Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.